Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: hepatitis B therapeutics - Janssen Sciences Ireland/University of the Witwatersrand

Next Previous
Drug Profile

Research programme: hepatitis B therapeutics - Janssen Sciences Ireland/University of the Witwatersrand

Alternative Names: Anti-HBV TALENs - Janssen Sciences Ireland/University of the Witwatersrand; Anti-HBV therapy - Janssen Sciences Ireland/University of the Witwatersrand

Latest Information Update: 28 Jul 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Sciences Ireland UC; University of the Witwatersrand
  • Class Antivirals
  • Mechanism of Action DNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis B

Most Recent Events

  • 28 Jul 2019 No recent reports of development identified for research development in Hepatitis-B in South Africa
  • 11 Jun 2015 The University of the Witwatersrand and Janssen Sciences Ireland UC agree to co-develop gene therapy in South Africa for Hepatitis B treatment
  • 11 Jun 2015 Early research in Hepatitis B treatment in South Africa (unspecified route)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top